A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours

BACKGROUND: This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimus-resistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436). PATIENTS AND METHODS: In stage 1, 11 patients received 400 mg BEZ23...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Anticancer Res
Main Authors: FAZIO, NICOLA, BUZZONI, ROBERTO, BAUDIN, ERIC, ANTONUZZO, LORENZO, HUBNER, RICHARD A., LAHNER, HARALD, DE HERDER, WOUTER W., RADERER, MARKUS, TEULÉ, ALEXANDRE, CAPDEVILA, JAUME, LIBUTTI, STEVEN K., KULKE, MATTHEW H., SHAH, MANISHA, DEY, DEBARSHI, TURRI, SABINE, AIMONE, PAOLA, MASSACESI, CRISTIAN, VERSLYPE, CHRIS
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5076549/
https://ncbi.nlm.nih.gov/pubmed/26851029
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados